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Abstract
Neural tube defects (NTD) are among the 
most prevalent congenital malformations 
in man. Based on the molecular defect of 
Splotch , an established mouse m odel for 
NTD j and on the clinical association be­
tween NTD and Waardenburg syndrome 
(WS), mutations in the PAX3 gene can be 
expected to act as factors predisposing to 
human NTD. To test this hypothesis, 39 
patients with familial NTD were screened 
by SSC analysis for mutations in exons 2 
to 6 of the human PAX3 gene. One patient 
with lumbosacral meningomyelocele was 
identified with a 5 bp deletion in exon 
5 approximately 55 bp upstream of the 
conserved homeodomain. The deletion 
causes a frameshift with a stop codon al­
most immediately after the mutated site. 
Clinical investigation of the index patient 
indicated mild signs of WS type I. Varying 
signs of this syndrome were found to co* 
segregate with the mutation in the family. 
Our results support the hypothesis that 
mutations in the gene for PAX3 can pre­
dispose to NTD, but also show that, in 
general, mutations within or near the con­
served domains of the PAX3 protein are 
only very infrequently involved in familial
NTD.
(J  Med Genet 1995;32:52- 56)
which is expressed in defined regions of the 
developing neural tube and in various neural 
crest derived tissues,7 can cause N TD  in ho­
mozygous embryos.8 In the heterozygous state, 
Pax3 mutations do not cause but seem to pre­
dispose to NTD in a strain specific manner.910 
A similar situation may exist in humans, where 
mutations in the PAX3 gene are known to cause 
Waardenburg syndrome (WS) ,11M7 a condition 
which is occasionally associated with N T D .18-24 
Therefore, it is tempting to speculate that in 
man, too, mutations in the gene for PAX3 (also 
referred to as HuP2) constitute genetic risk 
factors for NTD. If so, their frequency should 
be increased in patients with this disorder.
Materials and m ethods
ASCERTAINMENT OF PATIENTS AND DNA 
ISOLATION
Patients were selected from the Dutch popu­
lation in collaboration with the patient or­
ganisation BOSK and from the records of the 
Nijmegen hospital departments. Thirty nine 
families were selected with more than one pa­
tient who had an affected third degree or closer 
relative (first cousin, great aunt, or great uncle 
of the proband) .3 Genomic DNA was isolated 
from one patient from every family according 
to the procedure of Miller et a i25 The types of 
NTD in the test patients were spina bifida (37), 
encephalocele (1), and craniorachischisis (1).
Neural tube defects (NTD) are congenital mal­
formations resulting from incomplete closure 
of the neural tube during early embryonic de­
velopment. In man, their prevalence at birth is 
about 1/1000. NTD are thought to result from 
an interaction between environmental and pre­
disposing genetic factors which interfere with 
the normal neurulation process.1 The in­
volvement of genetic factors is reflected by the 
increased recurrence risk for close relatives of 
patients. Only about 3% of all cases are familial 
and large families with multiple cases are ex­
tremely rare.23 Therefore, it is practically im­
possible to identify the underlying genetic 
factors by linkage studies.4 Elucidation of these 
factors is essential to understanding the patho­
genesis of NTD and for the identification of 
persons at risk of having affected offspring.
An alternative approach to shed more light on 
these genetic factors is the analysis of suitable 
animal models. In one of the models for NTD, 
Splotch, 15 mutations in the gene for Pax3, 6
SSC ANALYSIS
DNA fragments overlapping exons 2 to 6 of 
the human PAX3 gene were amplified by the 
polymerase chain reaction (PCR) from gen­
omic DNA together with 5' and 3' flanking 
intron sequences. Amplification was carried 
out in a total volume of 25 jil containing 50 ng 
of genomic DNA, 0*45 mmol/1 of each primer, 
0-1 mmol/1 dCTP3 0-4 mmol/1 dATP, 0'4 mmol/
1 dGTP, 0-4mmol/1 dTTP, 0-1 jil [a32P]dCTP 
(Amersham) in PCR buffer (50 mmol/1 KC1,
10 mmol/1 Tris-HCl, pH 8-3, 1 mmol/1 DTE, 
0 *001% gelatine, 1-5-6 mmol/1 MgCl2) with 
0*5 U Taq DNA polymerase (Boehringer 
Mannheim). Samples were denatured at 92°C 
for five minutes and then subjected to 35 cycles 
of amplification: 92°C for 50 seconds, 55°C 
for 50 seconds, 72°C for one minute 30 sec­
onds. Exon 2 was analysed as two partly over­
lapping fragments. The following primers were 
used for amplification (fig 1), some of which 
are identical to those reported by Tassabehji et
A  frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome 53
Exon 2 Exon 3 Exon 4 Exon 5 Exon 6
t___ t—1 1 t_____ 3 t_____ 3 L______3 t_____ 3
Figure 1 Schematic respresentation of the part of the PAX-3 gene that was subjected to mutation screening. The position 
of the conserved domains is indicated by filled boxes (paired domain) 3 a single hatched box (octapeptide), and double 
hatched boxes (homeodomain) . Arrowheads with connecting bars represent the amplification primers and amplified 
fragments. The vertical arrow marks the site of deletion.
alu: exon 2, 5' fragment (266 bp): 5'-GAA- 
GACTGCGAAATTACGTGCTGC-3' and 
5'-ACAGGATCTTGGAGACGCAGCC-3'; 
exon 23 3' fragment (208 bp): 5'-AAC- 
CACATCCGCCACAAGATCG-3' and 5'- 
GACCACAGTCTGGGAGCCAGGAGG-3'; 
exon 3 (237 bp): 5'-CACCTGGCCC- 
AGGGTACCGGGTAC-3' and 5'-CGGGG~ 
TAÄTAGCGACTGACTGTC-3'; exon 4 
(242 bp): 5 AGCCCTGCTTGTCTCAAC- 
CATGTG-3' and 5'-TGCCCTCCAAGT- 
CACCCAGCAAGT-3'; exon 5 (304 bp): 5'- 
GACTTGGATCAATCTCAGTTTT-3' and 
5 '-TAGGAC A C G G AGGTTT G G- 3 exon 6 
(250 bp) 5'-TT CAT C AGTGAAAT C CTT - 
AAATT-3' and 5'-CGCCTGGAAGTTACT- 
TTCTA-3'. Aliquots of the amplified DNA  
were mixed with one volume form amide dye 
buffer denatured at 95°C for five minutes3 and 
placed on ice; 4 j.il samples were loaded on a 5% 
non-denaturing polyacrylamide gel containing 
10% glycerol and on a similar gel without 
glycerol. Electrophoresis was for three to six 
hours at 35W and 5°C. The gels were dried 
and exposed overnight to Kodak X-omat S film 
in order to visualise the separate bands.
DIRECT SEQUENCING OF NORM AL MUTANT 
ALLELES
To determine the nature of the shifted bands 
in the SSC analysis, 4 \û of amplification prod­
uct was loaded on a 6 *6 % denaturing poly­
acrylamide gel. The gel was electrophoresed at 
60 W for three hours at room temperature, 
dried, and exposed overnight to Kodak X-omat 
S film to visualise the bands. Bands rep­
resenting wild type and mutant alleles were cut 
out of the gel. DNA was eluted from each of 
the gel slices in 50 pi distilled water for one hour 
at 37°C and reamplified under the conditions 
described above. Subsequently, the amplified 
DNA fragments were purified by electro­
phoresis on a 1% agarose gel (one hour, 10 V/ 
cm), allowed to migrate into ultra low gelling 
temperature agarose (Sigma) , and sliced out of 
the gel. This material served as substrate for 
direct sequencing using the Cycle Sequence 
Kit (BRL) according to the protocol of the 
manufacturer. Sequences were determined in 
two directions with the forward and reverse 
amplification primers after 5' end labelling with 
32P.
session of the conserved paired domain. The 
paired domain of the PAX3 gene is encoded 
by (part of) exons 2, 3, and 4 .26 In addition 
the PAX3 gene contains two other conserved 
domains: an octapeptide motif encoded by a 
segment of exon 4,26 and a homeodomain en­
coded by the 3' and 5' part of exons 5 and 
63 respectively.15 To test the hypothesis that 
mutations in the PAX3 gene might predispose 
to the development of N T D 3 genomic DNA 
was isolated from 39 patients of multiple case 
N T D  families and the exons were screened 
for mutations by SSC analysis (Materials and 
methods, fig 1). When exon 5 was analysed, 
not only the normal band pattern, but several 
additional bands were observed in the DNA of 
one patient (fig 2A). To evaluate this further, 
the amplification products were subjected to 
denaturing gel electrophoresis, which showed 
the presence of a heterozygous deletion (fig 
2B). The location and size of the deletion were 
determined by direct sequencing of the eluted 
allelic DNA fragments (Materials and meth­
ods). A 5 bp deletion was detected in exon 5 
approximately 55 bp upstream of the ho­
meodomain (fig 3A). This causes a shift in
the normal reading frame for translation with 
premature termination of polypeptide synthesis 
almost immediately downstream of the mut­
ated site (fig 3B).
Results
A PAX3 GENE MUTATION IN  A PATIENT W IT H  
SPINA BIFIDA
PAX3 belongs to 
scription factors,
a family of embryonic tran- 
which are related by pos
CLINICAL EXAMINATION OF THE PATIENT AND 
HER RELATIVES
Knowing that PAX3 mutations can cause WS27 
(MIM 193500), signs of this disorder could be 
present in the patient and some of her relatives. 
Therefore3 the family (fig 4) was clinically (re)- 
examined. The major signs of WS are a typical 
facies with dystopia canthorum as the most 
frequently observed characteristic, pigmentary 
disturbances like a frontal blaze of white hair3 
heterochromia irides, white eyelashes and 
leucoderma, and partial or complete cochlear 
deafness. WS follows an autosomal dominant 
pattern of inheritance with a wide variability of
« * o c \expressivity.
The index patient (III.5) was seen at the age 
of l l~  years. She was born with a lumbosacral 
meningomyelocele for which she was operated 
on shortly after birth. Because of developing 
hydrocephalus3 a ventriculoperitoneal shunt 
was inserted, She is mentally retarded. Her 
height is 128*5 cm (<3rd centile), she weighs 
26 kg (50th centile for height), and has an 
occipitofrontal circumference of 53-7 cm 
(50th—90th centile). She has dystopia can­
thorum (ICD 43 mm3 >97th centile; OCD 
85 mm, 50th centile), leading to blepharo- 
phimosis, broad and high nasal root, hy-




Figure 2 Molecular analysis of exon 5 of the PAX3 gene. 
Autoradiographs show the allelic band patterns obtained 
with (A) SSC  analysis and (B) denaturing gel analysis 
o f genomic DNA fivm  two control persons (lanes 1 and 2) 
and from a patient with spina bifida (lane 3). With 
DNA from the patient, SSC analysis shows bands with 
abnormal mobility in addition to the wild type bands, 
indicating the presence of a heteivzygous mutation in exon 
5. 0?t denaturing gel electwphomis the aberrant allele 
appears to be of reduced length owing to a deletion.
poplastic nasal alae* a round nasal tip* and 
smooth philtrum. There is a naevus above the 
right eye. The palate is high arched and there 
is dental crowding. Below the spina bifida she 
has a deep sacral pit. She has no heterochromia 
irides* no pigmentary disturbances* and no 
hearing loss.
The mother of the index patient (II.4) has a 
similar appearance with dystopia canthorum 
(ICD 41 mm* >97th centile; OCD 85 mm5 
25th~50th centile)* leading to blepharo- 
phimosis* brushy eyebrows* a high nasal root.
hypoplastic nasal alae* and a round nasal tip. 
She has vitiligo of the left hand and wrist. She 
has no heterochromia ir ides and no hearing 
loss.
The maternal grandfather of the index pa­
tient (1.2) has heterochromia irides and dys­
topia canthorum* but no pigmentary 
abnormalities and no long standing hearing 
loss. No abnormalities were seen on a pho­
tograph of the maternal grandmother (LI),
The maternal aunt of the index patient (II. 1) 
has no signs of WS. Another sister of the 
mother (II.3) was bom with a lumbar men­
ingomyelocele and hydrocephalus* but died at 
the age of 6 months without having left the 
hospital. It is unknown whether she had any 
sign of WS. No material was saved for genetic 
analysis.
Several sibs of the index patient 111.4* ILL 8*
III, 9* and III. 10, show the facial characteristics 
of WS. III.9 was born with a white forelock* 
which subsequently disappeared* and has uni­
lateral hearing loss. III.8 had poliosis.
These observations show that WS is indeed 
segregating in this family and that the index 
patient has a mild expression of this syndrome 
in combination with spina bifida. Based on the 
presence/absence of specific symptoms* three 
subtypes of Waardenburg syndrome are dis­
tinguished. WS-I (MIM 193500) and WS-II 
(MIM 193510) are characterised by the pres­
ence or absence of dystopia canthorum* re­
spectively* whereas the disorder is diagnosed 
as WS-III (MIM 148820) if limb deformities 
are among the symptoms. Accordingly* the 
present family can be categorised as having 
WS-I. So far* WS with NTD patients have only 
been reported in families with WS type I.
N M











CORRELATION BETWEEN MUTATION AND 
PHENOTYPE
The pattern of inheritance of WS is compatible 
with that of an autosomal dominant disorder. 
To investigate further the relationship between 
the clinical signs and the mutation discovered 
in the index patient* exon 5 was amplified from 
the DNA of all available persons and analysed 
by denaturing gel electrophoresis. As can be 
seen in fig 5* there is an exact correlation 
between the presence/absence of the abnormal 
allele and the phenotype (Z = +2*40 at 0 =  
0 -0).
B
Exon 4 Exon 5
M AGC GAG CGA GCC TCA GCA CCC Ser Glu Arg Ala Ser Ala Pro
Í C M
eTn
TOA GAT GAA GGC TCT GAT 
Ser Asp Glu Gly Ser Asp
, AGC GAG CGA GCC TCA GCA CCC XXX XXAGA TGA AGG CTC TGA 
M Ser Glu Arg Ala Ser Ala Pro Arg ***
Figiire 3 (A) DNA sequence of the normal (N) and mutant (M ) allele of exon 5 of a 
patient with spina bifida as shown by cycle sequencing. The boxed sequence in the normal 
allele is deleted in the mutant allele. The awvw marks the site of the deletion in the 
mutant allele. (B) Partial cDNA and protein sequence of the region containing the 
deletion as deduced from the cycle sequencing results. The mutant gene contains a 
premature stop codon shortly after the site o f the deletion. The boundary between exons 4 
and 5 is indicated by a venical bar.
D iscussion
The association between N TD  and WS is well 
documented. Interestingly* of the 11 patients 
with NTD and WS reported since 1988* eight 
represent familial cases of N T D .19"24 This in­
cludes the index patient of the present study* 
who had a maternal aunt with spina bifida. 
Apparently* there is an increased recurrence 
risk of NTD in families with WS* which cor­
roborates the common aetiology of both dis­
orders. The molecular defect in two other 
patients with WS and NTD has previously 
been reported.1215 Both cases concern missense 
mutations in exon 2 changing an amino acid 
within the paired domain of the PAX3 protein.
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Figure 4 Pedigree of the family with two closely related patients with lumbar meningomyelocele and hydrocephalus: the 
index patient III. 5 and her maternal aunt II. 3. All members were clinically examined for symptoms of WS. Those with a 
positive diagnosis of WS in addition to the index patient are indicated by shaded symbols.
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Figure 5 Cosegregation of the exon 5 deletion with 
symptoms of WS. All available members of the family 
were analysed for the presence of the mutant allele by PCR 
amplification of exon 5 and subsequent denaturing gel 
separation of amplified fragments, A ll members diagnosed 
as having WS symptoms appear to carry the mutant 
allele.
Here we show that mutations disrupting the 
open reading frame of the PAX3 gene may also 
be found in patients with WS and NTD.
Despite the fact that carriers of a PAX3 
mutation probably have an increased risk for 
NTD* in the present study only one of 39 
patients with familial N T D  was found to have 
such a mutation indicating that* in general* 
PAX3 mutations are an infrequent cause of 
familial NTD. However* SSC analysis is not 
completely sensitive* leaving the possibility that 
some mutations have not been detected by this 
method. Further* mutations could be present 
in exons 1* 7* or 8* which have not yet been 
examined in detail. Nevertheless* mutations 
within or near the conserved domains of the 
PAX3 protein are not likely to play a major 
role in familial NTD.
Because of the findings in Splotch mice* it is 
not surprising that N T D  may be present in 
humans carrying a mutation in the PAX3 gene. 
Homozygous Splotch embryos die on day 13 
of gestation and 50% have lumbosacral spina 
bifida. Heterozygous animals display pig­
mentary disturbances* but have a normally 
closed neural tube* yet breeding experiments 
have shown that a heterozygous Pax3 mutation 
influences the incidence of N TD  in animals 
already committed to N T D  development.9 10 
Apparently* in those animals the occurrence of 
NTD depends on a combination of pre­
determining factors. A similar situation may 
exist in humans* where additional factors may 
modify the phenotypic expression of the same 
PAX3 mutation in different persons. Spina 
bifida is not the only malformation of 
homozygous Splotch embryos. In 50% ex- 
encephaly is observed and congenital heart de­
fects also occur* which are regarded as the 
major cause of death. In humans* anencephaly 
and congenital heart defects do not seem to 
be associated with WS but* considering the 
influence of other genetic factors on the pheno­
type* it may be worth looking for PAX3 mut­
ations in patients with NTD and congenital 
heart defects.
The pathophysiological processes leading to 
NTD in Splotch have not yet been elucidated, 
Suggested mechanisms include delayed mi­
gration of neural crest cells and an abnormal 
curvature of the caudal region. More likely* 
these phenomena are secondary to a defect of 
the neuroepithelium* where the Pax3 gene is 
expressed before neural tube closure.10 The 
detection and functional characterisation of 
PAX3 gene mutations in patients with NTD  
may help to clarify the pathogenesis of NTD  
further.
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